Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial
Autore:
Keller, MB; Ryan, ND; Strober, M; Klein, RG; Kutcher, SP; Birmaher, B; Hagino, OR; Koplewicz, H; Carlson, GA; Clarke, GN; Emslie, GJ; Feinberg, D; Geller, B; Kusumakar, V; Papatheodorou, G; Sack, WH; Sweeney, M; Wagner, DK; Weller, EB; Winters, NC; Oakes, R; McCafferty, JP;
Indirizzi:
Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02906 USABrown Univ Providence RI USA 02906 Human Behav, Providence, RI 02906 USA Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA Univ Pittsburgh Pittsburgh PA USA Med, Dept Psychiat, Pittsburgh, PA USA Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA Univ Calif Los Angeles Los Angeles CA USA 90024 Los Angeles, CA 90024 USA NYU, Ctr Child Study, New York, NY USA NYU New York NY USANYU, Ctr Child Study, New York, NY USA Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada Dalhousie Univ HalifaxNS Canada niv, Dept Psychiat, Halifax, NS, Canada Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 Psychiat, Philadelphia, PA 19104 USA SUNY Stony Brook, Dept Child & Adolescent Psychiat, Stony Brook, NY 11794 USA SUNY Stony Brook Stony Brook NY USA 11794 hiat, Stony Brook, NY 11794 USA Ctr Hlth Res, Portland, OR USA Ctr Hlth Res Portland OR USACtr Hlth Res, Portland, OR USA Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA Univ Texas Dallas TX USA exas, SW Med Ctr, Dept Psychiat, Dallas, TX USA Univ Washington, Sch Med, Dept Psychiat, St Louis, MO USA Univ WashingtonSt Louis MO USA Sch Med, Dept Psychiat, St Louis, MO USA Grace 1 WK Hosp, Dept Psychiat, Halifax, NS, Canada Grace 1 WK Hosp Halifax NS Canada sp, Dept Psychiat, Halifax, NS, Canada Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON, Canada Univ Toronto Toronto ON Canada i Ctr, Dept Psychiat, Toronto, ON, Canada Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA Oregon Hlth Sci Univ Portland OR USA 97201 ychiat, Portland, OR 97201 USA New York State Psychiat Inst, New York, NY 10032 USA New York State Psychiat Inst New York NY USA 10032 New York, NY 10032 USA Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Galveston, TX 77550 USAUniv Texas Galveston TX USA 77550 at & Behav Sci, Galveston, TX 77550 USA Childrens Hosp Philadelphia, Dept Psychiat, Philadelphia, PA 19104 USA Childrens Hosp Philadelphia Philadelphia PA USA 19104 lphia, PA 19104 USA GlaxoSmith Kline, N Amer Med Affairs, Collegeville, PA USA GlaxoSmith Kline Collegeville PA USA r Med Affairs, Collegeville, PA USA
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 7, volume: 40, anno: 2001,
pagine: 762 - 772
SICI:
0890-8567(200107)40:7<762:EOPITT>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND TRIAL; OPEN-LABEL; IMIPRAMINE; AMITRIPTYLINE; OUTPATIENTS; DISORDER; CHILDREN; FLUOXETINE; MULTICENTER;
Keywords:
paroxetine; imipramine; major depression; adolescent;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Keller, MB Brown Univ, Sch Med, Dept Psychiat & Human Behav, 345 Blackstone Blvd, Providence, RI 02906 USA Brown Univ 345 Blackstone Blvd Providence RI USA 02906 2906 USA
Citazione:
M.B. Keller et al., "Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial", J AM A CHIL, 40(7), 2001, pp. 762-772

Abstract

Objective: To compare paroxetine with placebo and imipramine with placebo for the treatment of adolescent depression. Method: After a 7- to 14-day screening period, 275 adolescents with major depression began 8 weeks of double-blind paroxetine (20-40 mg), imipramine (gradual upward titration to 200-300 mg), or placebo. The two primary outcome measures were endpoint response (Hamilton Rating Scale for Depression [HAM-D] score less than or equal to8 or greater than or equal to 50% reduction in baseline HAM-D) and change from baseline HAM-D score. Other depression-related variables were (1) HAM-D depressed mood item; (2) depression item of the Schedule for Affective Disorders and Schizophrenia for Adolescents-Lifetime version (K-SADS-L); (3) Clinical Global impression (CGI) improvement scores of 1 or 2; (4) nine-item depression subscale of K-SADS-L; and (5) mean CGI improvement scores. Results: Paroxetine demonstrated significantly greater improvement compared with placebo in HAM-D total score less than or equal to8, HAM-D depressed mood item, K-SADS-L depressed mood item, and CGI score of 1 or 2. The responseto imipramine was not significantly different from placebo for any measure. Neither paroxetine nor imipramine differed significantly from placebo on parent- or self-rating measures. Withdrawal rates for adverse effects were 9.7% and 6.9% for paroxetine and placebo, respectively. Of 31.5% of subjects stopping imipramine therapy because of adverse effects, nearly one third did so because of adverse cardiovascular effects. Conclusions: Paroxetine is generally well tolerated and effective for major depression in adolescents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:38:34